ArriVent BioPharma (AVBP) Preferred Stock Liabilities (2023)

ArriVent BioPharma has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $154.6 million for Q4 2023.

• Preferred Stock Liabilities for Q4 2023 came in at $154.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $154.6 million (changed N/A YoY), and the FY2023 annual result was $154.6 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $154.6 million for Q4 2023 at ArriVent BioPharma, roughly flat from $154.6 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $154.6 million in Q1 2023 to a low of $149.9 million in Q2 2023.